Tyrosinekinase inhibitorsLeukemic stem cellsInterferon.Chronicyeloid leukemia (CIVIL) isalignant disorder in whichhe immuneystemaseen describeds importantorhe graft versus leukemia effectftertemellransplantation. With imatinibt dosef 400g,heurrentreatmentfhronic phaseML does not eradicatehe leuke,icte...
Meyer T. Inhibitors of protein kinases : CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. 1999 ; 82 : 293-301.doi:10.1016/S0515-3700(08)70234-9Sébastien FaureMaître de conférences des Universités, Faculté de pharmacie, Angers (49);elsevier...
The results from the semi-parametric FELW2ST approach shows that, except for Mexico, stock price indices of 13 emerging markets are not mean reverting.doi:10.1016/S0515-3700(10)70754-0Françoise Couic MarinierActualités Pharmaceutiques
Many skin reactions have been described in patients on nilotinib and sunitinib, but few publications report the development of de novo ulcers in patients without risk factors. The pathophysiology of the development of ulcers in patients receiving tyrosine kinase inhibitors is not clear, and probably ...
tyrosine kinaseiatrogenic pathologyIatrogenic causes for palpebral edema are rarely suspected and must be specifically sought. The authors report a case of palpebral edema in a patient treated with a specific inhibitor of the BCR-ABL tyrosine kinase (Glivec) for chronic myeloid leukemia. ...
doi:10.1016/j.annder.2018.04.009Krygier J.Leemans G.Forsyth R.de Becker A.Gutermuth J.Grosber M.Annales de Dermatologie et de Vénéréologie